The Science Behind NAD+ Therapy: What You Need to Know

If you are over 40 and the afternoon slump has started to feel less like a habit and more like a system failure, you are not imagining things. Energy, focus, recovery, and resilience all depend on a coenzyme that almost nobody talks about by name: nicotinamide adenine dinucleotide, or NAD+. It is one of the most-studied molecules in modern longevity research, and the picture coming out of human trials is more nuanced — and more interesting — than the supplement-aisle pitch suggests.

This is a careful look at what NAD+ does, why levels appear to fall with age, what NAD+ precursors and injections have actually been shown to do in people, and how to think about NAD+ therapy as one part of a larger wellness plan.

What NAD+ is, in plain language

NAD+ is a coenzyme present in every living cell. It participates in hundreds of biochemical reactions, but three jobs matter most for how you feel after 40:

• Mitochondrial energy production. NAD+ shuttles electrons through the reactions that turn food into ATP — the chemical currency of every contraction, thought, and immune response.
• DNA repair. Enzymes called PARPs use NAD+ to find and patch DNA damage. The more wear and tear your cells face, the more NAD+ this work consumes.
• Sirtuin activation. A family of proteins called sirtuins — sometimes nicknamed "longevity enzymes" — depend on NAD+ to regulate inflammation, metabolism, and stress resistance.[1][2]

Researchers have characterized NAD+ as sitting at a kind of metabolic crossroads, where energy, repair, and gene expression all meet.[1] When NAD+ supply is adequate, those systems run smoothly. When it falls, the effects ripple outward.

Why NAD+ may decline with age — and what the evidence actually shows

You have probably read that NAD+ drops by 50% between your 20s and your 50s. That headline is rooted in real science, but it deserves more nuance than it usually gets.

A 2012 PLOS ONE study by Massudi and colleagues found that NAD+ concentration in human skin samples declines substantially across adult aging, providing the foundation for the widely cited "~50% decline" figure.[3] However, more recent reviews — including critical analyses of the field — note that human estimates of NAD+ decline vary widely across tissues and methodologies, with reported differences ranging from minimal to substantial depending on what is measured.[1][2] In other words: NAD+ does appear to fall with age, but the rate and magnitude depend heavily on the tissue and the assay.

What is more consistent is the direction of the change and the mechanisms behind it. As we age, NAD+-consuming enzymes such as CD38 and PARPs become more active in response to inflammation and accumulating DNA damage, while the enzymes that recycle and synthesize NAD+ become less efficient.[1][2] The result is a slower, more constrained NAD+ economy — one that may help explain why mitochondria, DNA repair, and sirtuin-driven housekeeping become less robust over time.

What happens when NAD+ goes up: the human trial evidence

The most rigorous data on NAD+ in humans comes from trials of oral precursors — primarily nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — that the body converts into NAD+ through enzymatic steps.

A randomized, multicenter, double-blind, placebo-controlled trial published in GeroScience studied 80 healthy middle-aged adults given placebo or 300, 600, or 900 mg of NMN daily for 60 days.[4] Blood NAD concentrations increased significantly in the NMN groups versus placebo, with improvements in six-minute walking distance and subjective health, and no safety signals identified during the trial.

A 2024 randomized, placebo-controlled study in older adults published in GeroScience by Morifuji and colleagues found that 250 mg/day of NMN for 12 weeks raised blood NAD+ and related metabolites, with secondary improvements in 4-meter walking time and Pittsburgh Sleep Quality Index scores.[5]

A separate 2022 npj Aging trial in healthy older men gave 250 mg/day of NMN for 12 weeks and reported significant increases in blood NAD+, with a nominally significant improvement in left-hand grip strength only — a small effect the authors stated "should be validated in larger studies."[6]

In a 2021 Science paper, Yoshino and colleagues studied postmenopausal women with prediabetes who were overweight or obese.[7] After 10 weeks of 250 mg/day NMN, the supplemented group showed improved muscle insulin sensitivity, insulin signaling, and muscle remodeling markers compared with placebo. This is an important nuance often missed in summaries: the population was specifically overweight or obese with prediabetes — not the general public.

On the NR side, a 21-day trial in older men published in Cell Reports by Elhassan and colleagues found that 1 g/day of NR raised the NAD+ metabolome in skeletal muscle and downregulated energy-metabolism and inflammatory pathways.[8] And the NADPARK study published in Cell Metabolism by Brakedal and colleagues showed that NR was safe and increased cerebral NAD+ in a phase I trial of patients newly diagnosed with Parkinson's disease.[9] (That study is not a wellness study and should not be over-extrapolated, but it is meaningful proof that oral NR can change NAD+ levels in human brain tissue at all.)

Finally, a 2024 randomized placebo-controlled trial in GeroScience by Orr and colleagues gave NR to older adults with mild cognitive impairment.[10] Blood NAD+ increased 2.6-fold (p<0.001). The study also examined two epigenetic-age clocks, PhenoAge and GrimAge, and reported a non-significant trend toward reduced epigenetic age in the NR group — paired t-tests did not reach statistical significance, so this finding is hypothesis-generating rather than confirmatory.

The honest summary across this body of work is that human NAD+ precursor trials reliably raise NAD+ or NAD+-related metabolites in blood, with some secondary signals on physical function, sleep, insulin sensitivity, and cerebral NAD+ status. None of these trials show that NAD+ therapy "reverses aging." They show something more useful: a pathway that can be moved, in humans, in ways that may be relevant to healthy aging.

Precursors vs. injectable NAD+: a real distinction

It is tempting to lump every NAD+ product into one bucket. That is a mistake. Most published human trials study oral NMN or NR — not injectable NAD+ itself. The two should not borrow each other's claims uncritically.

That said, the rationale for injectable NAD+ is straightforward. Oral precursors must survive digestion, cross the gut wall, and be enzymatically converted before they can support cellular NAD+ pools. Bioavailability varies between people, and conversion efficiency may decline with age. Injectable NAD+ — typically subcutaneous in a prescription wellness setting — bypasses first-pass metabolism and enters circulation directly.

What injectable NAD+ does not have, yet, is the same depth of published placebo-controlled outcome data that oral NR and NMN have. This is why responsible providers position injectable NAD+ as a clinician-supervised intervention with reasonable mechanistic logic and growing real-world experience, rather than as a finished science. Patient selection, dosing, and oversight matter.

What the evidence does not say

Wellness marketing has a way of running ahead of the data. A few things NAD+ research does not support:

• NAD+ therapy does not "reverse aging."
• It does not cure fatigue, depression, neurodegenerative disease, or weight gain.
• It does not replace standard medical care for thyroid, iron, B12, sleep apnea, hormonal, or metabolic conditions.
• It is not a substitute for sleep, training, nutrition, or stress recovery.

The honest framing is that NAD+ sits close to the cellular machinery of energy and repair, and emerging human trials suggest the pathway can be supported. That is meaningful — but it is not the same as saying NAD+ does any one specific thing for any one specific person.

Who might be a good fit for NAD+ therapy

NAD+ therapy is most often considered by adults in their late 30s through their 60s who have already addressed the foundations — sleep, training, protein-forward nutrition, alcohol moderation, stress recovery — and want clinician-supervised cellular support to layer on top.

Common goals include:

• Sustained daytime energy and reduced afternoon fatigue
• Faster recovery from exercise and physical stress
• Mental clarity and steadier focus
• Support for healthy aging alongside other longevity-minded habits

What it should never be is the first intervention for new, severe, or unexplained symptoms. Persistent fatigue, brain fog, weight changes, or sleep disruption deserve a proper medical workup first.

How RenuviaRX approaches NAD+

At RenuviaRX, NAD+ therapy is delivered as a physician-supervised subcutaneous injection program. Patients begin with an online assessment reviewed by a board-certified physician, who determines eligibility, screens for contraindications, and personalizes the protocol. Compounded NAD+ is prepared by Strive Pharmacy and shipped directly. Plans start at $179/month, with consultation and free shipping included.

The point of the medical layer is not theater. It is making sure the right people get the right intervention for the right reasons — and that NAD+ therapy fits into a larger plan that includes whatever else matters for your health.

The bottom line

NAD+ is not a magic molecule. It is a foundational coenzyme that sits close to the systems most of us care about as we age: energy, repair, metabolism, focus, and resilience. The human research base — though still maturing — increasingly suggests the NAD+ pathway is responsive to targeted support, with measurable effects on blood NAD+ levels and signals on physical function, sleep, and cellular metabolism.[4][5][6][7][8][9][10]

If you are ready to explore whether NAD+ therapy fits your wellness goals, start with a free physician assessment.

Take the Assessment →

---

References

1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. "NAD+ metabolism and its roles in cellular processes during ageing." Nature Reviews Molecular Cell Biology, vol. 22, no. 2, 2021, pp. 119-141. DOI: 10.1038/s41580-020-00313-x

2. Yusri K, Jose S, Vermeulen KS, Tan TCM, Sorrentino V. "The role of NAD+ metabolism and its modulation of mitochondria in aging and disease." npj Metabolic Health and Disease, vol. 3, 2025, article 26. DOI: 10.1038/s44324-025-00067-0

3. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. "Age-associated changes in oxidative stress and NAD+ metabolism in human tissue." PLOS ONE, 2012.

4. Yi L, Maier AB, Tao R, et al. "The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience, vol. 45, no. 1, 2023, pp. 29-43. DOI: 10.1007/s11357-022-00705-1

5. Morifuji M, Higashi S, Ebihara S, Nagata M. "Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study." GeroScience, 2024. DOI: 10.1007/s11357-024-01204-1

6. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging, vol. 8, no. 1, 2022, article 5. DOI: 10.1038/s41514-022-00084-z

7. Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, vol. 372, no. 6547, 2021, pp. 1224-1229. DOI: 10.1126/science.abe9985

8. Elhassan YS, Kluckova K, Fletcher RS, et al. "Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures." Cell Reports, vol. 28, no. 7, 2019, pp. 1717-1728. DOI: 10.1016/j.celrep.2019.07.043

9. Brakedal B, Dölle C, et al. "The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease." Cell Metabolism, vol. 34, no. 3, 2022, pp. 396-407. DOI: 10.1016/j.cmet.2022.02.001

10. Orr ME, Kotkowski E, Ramirez P, et al. "A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment." GeroScience, vol. 46, no. 1, 2024, pp. 665-682. DOI: 10.1007/s11357-023-00999-9

---

The information in this article is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.